Lawsuit Intelligencer Vol. I · No. 7 · November 2026

Lawsuit Intelligencer

Attorney-led analysis of mass torts, product liability, toxic exposure litigation, and the business of plaintiff-side law.

Analysis · Mass Torts & MDL Practice

The 2026 Mass Tort Map

The federal docket has never been more concentrated, and 2026 is the year the procedural phase finally turned into verdicts. Two of the defense bar's most dependable shields are cracking at the same time: Section 230 and bankruptcy.

The monthly letter carries this map’s monthly changes, the Panel’s biggest docket moves and the MDLs you follow, once a month. Sign up →

The docket at a glance

204,987
pending actions, up 10 from October
164
active MDLs, up from 162 in October
~94%
of pending actions sit in mega-dockets

The Panel’s November 2, 2026 report can be read by courthouse. The mass tort dockets, 73 of the 164 on the report, hold 201,243 of its 204,987 pending actions and sit in 27 districts.

Four courts hold the mass of the system. New Jersey carries talc and proton-pump inhibitors. Southern Ohio carries Bard hernia mesh, South Carolina carries AFFF, and Northern Illinois carries hair relaxer and NEC infant formula. The Northern District of California holds the most mass tort dockets, twelve.

Hover a district for its totals. Click one to list its dockets and filter the board below to that court. The commercial dockets, antitrust and data breach among them, are one toggle away.

Interactive · A Where the dockets sit · pending MDLs by district, November 2, 2026

Each bubble marks a transferee court, sized by the district’s pending actions or by its count of MDLs. Where courts sit close together, bubbles are nudged apart and a thin line points back to the courthouse. The mass torts view shows the 73 mass tort dockets on the report. The All MDLs view shows every docket on it. Source: JPML pending-dockets report, November 2, 2026.

Every mass tort docket on the Panel’s report is on the board below. That means the products liability MDLs, plus the assault, opiate, concussion and turnout gear dockets the Panel files under other headings. The commercial dockets sit behind their own chip. Sort any column, or search by product, defendant, court or judge. The change column compares the November 2, 2026 and October 1, 2026 reports. The last column sketches the past twelve months for the 34 dockets this page tracks.

Interactive · B The docket board · 73 mass tort MDLs on the November 2, 2026 report

MDL Docket Type Court Oct 1 Nov 2 Change % 12 mo

Pending actions from the JPML reports of October 1, 2026 and November 2, 2026. Mass torts here means the 65 products liability dockets plus eight personal injury dockets the Panel files under other headings. Those eight are Uber, Lyft and Roblox assault, the opiate MDL and its McKinsey companion, the NFL and NCAA concussion dockets, and firefighter turnout gear. Commercial gathers the rest.

A blank Oct 1 cell marks a docket created after that report. Those are Abbott spinal cord stimulator (MDL 3194), Nevro spinal cord stimulator (MDL 3195), Amazon tariff refunds (MDL 3197) and Apple AirTag stalking (MDL 3199). Two dockets left the report between the two months: Blackbaud (MDL 2972) and Generac Solar Power Systems (MDL 3078).

Five dockets sit at zero pending actions. Three are on the mass tort board: J&J sunscreen (MDL 3015), Ethicon Physiomesh (MDL 2782) and Zostavax (MDL 2848). Two are under Commercial: Clearview AI privacy (MDL 2967) and the crop protection antitrust docket (MDL 3062). A zero means every transferred action has been closed or remanded and the Panel has not yet entered the order terminating the MDL.

The short version

  • The system holds 204,987 pending actions across 164 active MDLs as of the November 2, 2026 report, up 10 from October 1, 2026. About 12% of dockets hold ~94% of the cases, and J&J talc alone is roughly a third of everything.
  • Depo-Provera went from surge to settlement. The fastest-growing docket of the cycle reached a global settlement in principle on June 15, with terms undisclosed. Filings kept arriving through the September report and then stopped.
  • 2026 is the bellwether year. The first social-media design-defect verdict landed against Meta and YouTube. The first Bard PowerPort bellwether split. The first federal social-media bellwether settled before it reached a jury.
  • Two structural defenses cracked at once. Plaintiffs reframed platform harm as product design, beat Section 230 at trial, and in August the Ninth Circuit held the statute is a defense rather than immunity from suit. J&J’s third attempt to cap talc liability through Chapter 11 was dismissed, and the company now proposes to pay $5.5 billion.
  • JPML gatekeeping is sharp. Roblox child-exploitation claims were centralized; a video-game "addiction" theory naming the same platform was refused weeks earlier. On October 2 the Panel refused an industry-wide spinal cord stimulator docket and gave each manufacturer its own.

1. The shape of the docket

Read in aggregate, the federal mass tort system looks enormous and sprawling. Read by where the cases actually sit, it looks like a short list of mega-dockets with a long tail trailing behind them. As of the JPML's November 2, 2026 report, the system held 204,987 pending actions across 164 active multidistrict litigations, up from 204,977 across 162 a month earlier. The distribution is so lopsided that the headline count is almost the least useful number in it.

Dockets carrying 1,000 or more pending actions make up only about an eighth of all active MDLs, yet they hold the overwhelming majority of the cases. The concentration is not a quirk of one big year. It is the structural fact that shapes leadership appointments, settlement leverage, and where the plaintiff bar spends its advertising dollars.

Within that top tier, one docket dominates everything else. Johnson & Johnson's talc litigation alone accounts for roughly a third of all pending federal MDL actions, more than the next several dockets combined. That is why a single bankruptcy ruling in Texas can move the entire system's case count.

2. The growth is inside the mega-dockets

The long arc for active MDLs is still flat to slightly declining, down from roughly 170 in early 2025 to 159 this spring. The count climbed back to 166 by September and gave up four dockets in October. October was also the first month this cycle in which the pending-action total fell.

What grows is the size of the dockets that already dominate. Talc is the clearest illustration. The count climbed steeply through mid-2025 and plateaued near 67,000–68,000 after the proposed bankruptcy exit ramp collapsed. It then resumed climbing at roughly 400 cases a month, adding 406, then 479, then 336 across the July, August and September reports.

The October report added 90 and the November report 36. That slowdown began after J&J’s settlement proposal, and whether it holds is the number to watch. Fig. 3 carries the three newest reports.

J&J proposed a $5.5 billion resolution on July 27 covering roughly 76,000 ovarian cancer claims across federal and state courts. The offer is conditioned on 95% claimant participation, with the first payment capped at $3 billion in 2027. A deal that needs 95% of a pool to sign is priced against a pool that kept growing for three reports after it was announced.

The opposite shape, near-vertical growth that ran straight into a settlement, belongs to Depo-Provera. The docket added roughly 1,700 cases in a single report this spring, the largest one-month gain of any MDL this cycle. On June 15 Pfizer and plaintiffs’ leadership disclosed a global settlement in principle. Terms were undisclosed, eligibility was limited to cases pending in the MDL, and the first bellwether was vacated.

Filings did not stop. Another 322 arrived in the July report, 464 in August and 109 in September. The October report added 9 and the November report 1. The docket has stopped taking on cases.

For anyone tracking where intake advertising and referral volume are flowing, this is no longer a growth story. It is an eligibility-window story, and the window is now the whole game.

What makes this docket worth watching is that the settlement and the science are being built at the same time. Pfizer and plaintiffs’ leadership signed a master settlement agreement on July 21, with terms confidential and the parties estimating that roughly 80% of MDL plaintiffs qualify. Registration is expected to run through November, with payments projected to begin in the first quarter of 2027.

Judge Rodgers appointed a settlement administrator on August 5. On September 4 she issued three orders in one day, naming an allocation master for the supplemental compensation fund, a qualified settlement fund administrator, and a lien resolution administrator. An administrative docket dedicated to the settlement followed on September 15.

Alongside that machinery sits a fully briefed Rule 702 record. Plaintiffs moved on August 5 to exclude five defense experts across the pilot cases. Pfizer moved the next day to exclude the plaintiffs’ general causation experts. Briefing closed on August 7 and the general-causation hearing was set for September 18. No ruling has issued. Judge Rodgers has status conferences set for November 20 and December 14.

On October 16 the lead lawyers reported that settlement registration is open and closes November 30. The court’s own count that day was 6,451 cases covering 6,775 women.

That parallel posture is the thing to read. A settlement in principle usually slows the merits track. Here the court issued a case management order for ongoing litigation five days after appointing the settlement administrator, and conditional transfer orders are still bringing new cases in.

A defense ruling on the September record would leave the deal intact while stripping the value out of every claim sitting outside it. That is precisely the exposure the eligibility window was drawn to contain. The October and November reports, with 9 and then 1 new cases, suggest the filing bar read that risk the same way.

The two charts above follow one docket each. The tiles below follow every mass tort docket this page tracks, each on its own scale, from the February 2025 report to November 2026. The figure on each tile is the Nov 2 count; the change is over the past twelve reports. Click up to four tiles to lay them over one another in the chart underneath.

Interactive · C Trend lines · pending actions by month, Feb 2025–Nov 2026

Monthly pending actions from the JPML’s by-actions-pending reports, February 2025 through November 2, 2026. Each tile runs on its own scale, so compare shapes between tiles and read sizes from the figures. A line starts in the first report that lists the docket. The indexed view sets each docket’s first month to 100 on a log scale, so a doubling is the same height anywhere on it.

The docket focus below follows one MDL at a time. Pick a docket and a window of one, three, six or twelve reports. The panel gives the current count, the change over the window and the largest one-month move. It splits that change into new cases docketed and cases closed, which shows whether a docket stalled because filings stopped or because cases left. It also fits a trendline to the window and sets the docket’s change beside the change across all MDLs.

The panel opens on AFFF. Any view can be linked: the address of this page followed by #focus-2873-6 opens AFFF over six reports.

Interactive · D Docket focus · one MDL over the window you pick

Monthly pending actions from the JPML’s by-actions-pending reports, February 2025 through November 2, 2026. The dashed line is a least-squares fit to the reports inside the window. Its pace is the fitted change per monthly report. R² runs from 0 to 1 and shows how closely the reports follow that line.

Each JPML report also counts every action ever docketed in the MDL. New cases docketed is that count’s rise from one report to the next. Cases closed is new cases minus the change in pending, so it counts dismissals, remands and settled cases together. The JPML sometimes trims its running total by a few actions; a bar for that month shows zero. The report counts actions, and one action can name many plaintiffs.

The projection extends the same line one report ahead and assumes the pace holds. The zoomed scale starts near the window’s lowest count, which makes small moves look large. From zero shows the docket at true size. Use the arrow keys on the chart to step through the reports.

Where the growth actually went this month

The table ranks the dockets by their change between the Panel’s two newest reports. The notes under it name the ruling or settlement behind a move where the court record shows one.

Largest moves · October 1, 2026 to November 2, 2026: the ten biggest gains, then the biggest drops
DocketOct 1Nov 2Change
Social media adolescent addiction (MDL 3047)3,8244,309+485 · +12.7%
Hair relaxer (MDL 3060)12,38112,743+362 · +2.9%
Bard PowerPort catheter (MDL 3081)4,1404,345+205 · +5.0%
GLP-1 (GI injury) (MDL 3094)4,0254,082+57 · +1.4%
J&J talc (MDL 2738)69,34069,376+36 · +0.1%
Paraquat (MDL 3004)6,6026,635+33 · +0.5%
GLP-1 NAION vision loss (MDL 3163)247278+31 · +12.6%
Boston Scientific spinal cord stimulator (MDL 3181)4162+21 · +51.2%
September 11 terrorist attacks (MDL 1570)380396+16 · +4.2%
Roblox child sexual exploitation (MDL 3166)180196+16 · +8.9%
NCAA concussion (MDL 2492)549166−383 · −69.8%
Uber passenger sexual assault (MDL 3084)4,9164,548−368 · −7.5%
Baby food heavy metals (MDL 3101)497286−211 · −42.5%
Roundup (MDL 2741)1,104916−188 · −17.0%
Paragard IUD (MDL 2974)4,2244,104−120 · −2.8%

Read the percentage column separately from the count column. A docket of a few dozen actions can grow by half in one report, which is a signal about one small docket rather than about the system.

System-wide pending actions rose by 10 between the two reports. The dockets that grew added 1,383. The dockets that shrank gave up 1,426, the four new MDLs brought 87, and the two that closed took 34 with them.

Behind the November 2 moves. Depo-Provera held the growth title for most of the cycle. The social-media docket took it in the October report and kept it in November, adding 616 actions and then 485. That docket sits in the Northern District of California before Judge Gonzalez Rogers.

Hair relaxer added 362 in the month Judge Rowland admitted the plaintiffs’ core causation experts. Bard PowerPort added 205. Boston Scientific grew by half, on a base of 41 actions.

Uber passenger assault is the one to read closely. It took in 331 new actions and closed 699, so the net drop hides filings that have not slowed. NCAA concussion closed 383 of its 549 actions with no new filings.

Baby food fell by 211 after Judge Corley’s October 14 partial summary judgment ended the autism and ADHD claims. Roundup gave up another 188 as settled cases closed. Paragard fell by 120 after Judge May granted Teva’s second motion to dismiss time-barred cases on October 28.

The JPML report states the count and not the reason, so confirm the mechanism in the transferee court’s docket before building an argument on it. The docket focus splits each month’s change into new cases and cases closed.

3. The bellwether turn

For most of the last three years, the mega-dockets generated motion practice, not verdicts. That changed in the first half of 2026. Within roughly six months, the litigation produced the first jury verdict in the social-media docket and the first bellwether result in Bard PowerPort. The same stretch brought a reset of the AFFF personal-injury track and a string of state-court talc rulings. That is the moment a docket stops being a filing statistic and starts pricing risk.

The second half of the year added the other half of the lesson: three of the largest dockets reached for settlement machinery before a second jury could be seated.

Social media: from "untested" to a plaintiff verdict

For three years the social-media docket was a Section 230 argument with no money changing hands. In early 2026 the lead California state-court bellwether broke that pattern. TikTok and Snap settled confidentially before trial. On March 24 a jury found Meta and Google/YouTube liable for negligently designing platform features that harm adolescent users. The verdict followed a ruling that neither Section 230 nor the First Amendment barred the design-defect theory.

The first federal MDL bellwether never reached a jury. The Breathitt County school-district case settled with all four platforms in May, for a reported figure near $27 million, weeks before its June 15 trial date. Meta then resolved the state attorneys general cases on August 26. It agreed to pay 47 states up to $17.1 billion over ten years and to change teen-safety defaults on Instagram and Facebook. That money goes to state programs, and the consent judgment preserves the personal-injury and school-district claims.

The second California family bellwether never reached a jury. Jury selection began October 28 in Los Angeles without TikTok, which had settled, and Meta and Snap settled with both plaintiffs by November 2. The first federal school-district trial, Tucson Unified, is set for February 8, 2027.

Bard PowerPort: a "defense verdict" that wasn't clean

The first federal PowerPort bellwether went to a jury in Arizona and produced a partial defense verdict. The manufacturer prevailed on failure-to-warn, failure-to-instruct, and consumer-fraud claims, but the jury hung on the central design-defect question. Calling it a defense win overstates it. Additional bellwethers run through early 2027, and in July the court pushed the parties into settlement discussions.

AFFF: water resolved, personal injury reset

The PFAS story has split cleanly. The public-water track is largely resolved through large settlements with the principal chemical defendants. The personal-injury track is organized around a defined set of qualifying conditions, with kidney cancer as the lead. Its first bellwether was pulled off the October calendar and reset, even as the inventory of unfiled claims runs into the tens of thousands.

4. Two structural defenses under pressure

The throughline of 2026 is not any single verdict. It is that two defenses the corporate bar has relied on for years showed cracks in the same window.

Plaintiffs stopped litigating what users posted and started litigating how the product was built. That reframing is what carried a verdict past Section 230.

Section 230. The platform-immunity statute was built for liability over third-party content. The plaintiff bar's move was to stop suing over content and start suing over design: algorithms, notification cadence, infinite scroll, the architecture of engagement. Courts have increasingly let that theory through, and a jury has now accepted it.

The Ninth Circuit then narrowed what the statute does. On August 10 it dismissed the platforms’ interlocutory appeal as premature, holding that Section 230 supplies a defense to liability rather than an immunity from suit. A defendant that must try the case first and raise the statute on appeal from a final judgment is a defendant that carries trial risk on every file. The design-defect lane around the statute is now a proven path rather than a hopeful one.

Bankruptcy. The other shield is the use of Chapter 11 to corral and cap mass-tort liability. J&J's third attempt, the "Texas two-step" via a purpose-built subsidiary, was dismissed, with the court pointing to irregularities in how claimant support was tallied. The proposed multibillion-dollar resolution evaporated, and roughly 90,000 claims returned to active litigation. The lesson for any defendant eyeing the divisional-merger route is that the maneuver is getting harder to land.

What replaced it says as much: on July 27 J&J proposed a $5.5 billion resolution in the tort system, conditioned on 95% participation and excluding mesothelioma and future claims.

The company is also pressing an evidentiary attack in parallel. Plaintiffs withdrew two specific-causation experts in May after a special master faulted their methodology. On July 22 Magistrate Judge Singh ordered plaintiffs to show why the remaining talc claims should not be dismissed for failure to prove specific causation. A defendant that loses the bankruptcy shield can still litigate the proof.

5. What the JPML centralizes, and what it refuses

The Panel's gatekeeping in this cycle rewards two things: a clearly defined injury and a recognizable, bounded set of defendants. Where either is missing, centralization tends to fail. The sharpest illustration came weeks apart, around the same product.

JPML gatekeeping · selected 2025–2026 rulings
Petition / docketTheoryResult
Roblox child sexual exploitation (MDL 3166)Platform-safety failure; facilitated exploitationCentralized · Dec 2025
"Gateway games" video-game addictionAddiction across multiple platforms/publishersDenied · Dec 2025
Lyft passenger sexual assault (MDL 3171)Driver assault; mirrors Uber docketCentralized · Feb 2026
GLP-1 NAION vision loss (MDL 3163)Distinct injury split from GI-injury docketCentralized · Dec 2025
ByHeart infant formula (MDL 3178)Contamination / product liabilityCentralized · Apr 2026
Spinal cord stimulators, industry-wideOne docket for Abbott, Nevro and Boston Scientific devicesDenied · Oct 2026
Abbott and Nevro spinal cord stimulators (MDLs 3194, 3195)Device injury; one manufacturer per docketCentralized separately · Oct 2026
Apple AirTag (MDL 3199)Design that allowed stalking; uniform claims against one companyCentralized · Oct 2026
NCAA eligibility rules antitrustChallenges to different rules at different stagesDenied · Oct 2026
Gastric cancer case into PPI docket (MDL 2789)Non-kidney injury outside the docket’s scopeTransfer denied · Oct 2026

The contrast in the first two rows is the whole lesson. A theory built on a defined harm and a single defendant was centralized. A broader "addiction" theory that would have swept in multiple publishers and an open-ended product universe was refused. The same logic explains the GLP-1 split into two MDLs by injury type. It is the single best predictor of which emerging theory becomes a docket and which stays a press release.

The Panel’s October 2 orders applied that logic four times in one day. Some parties asked for a single spinal cord stimulator docket covering Abbott, Nevro and Boston Scientific. The Panel refused, finding that each manufacturer has its own device line and regulatory history, so discovery into one company’s conduct would not overlap with another’s.

It then centralized the Abbott claims in the Northern District of Illinois before Judge Jenkins and the Nevro claims in the Northern District of California before Judge Gilliam. The Boston Scientific docket stays in the Central District of California, so one device category now runs in three courts.

The AirTag order points the same way from the other side. Apple opposed centralization, and the Panel overruled it because every plaintiff alleges that the same design choices let a stalker track them. The Panel also noted that Apple has received tens of thousands of stalking complaints, a sign that the docket will grow. The two refusals fit the pattern too. The NCAA eligibility cases challenged different rules at different stages, and a gastric cancer case could not join a proton-pump inhibitor docket built around kidney injury.

The GLP-1 dockets are where that split is now being stress-tested, and the numbers show why the division mattered. The gastrointestinal docket (MDL 3094) passed 4,000 pending actions in the September report. The NAION docket (MDL 3163) opened the year with 29 actions and held 278 by the November report. The docket focus carries the current count for each.

Neither is close to the top ten. Both sit before Judge Marston in the Eastern District of Pennsylvania, which means the same court is running two causation records built on different science.

The gatekeeping inside MDL 3094 has been more consequential than its size suggests. In a memorandum order entered August 15, 2025, the court resolved the first cross-cutting issue against the plaintiffs. It excluded two of their experts on whether gastroparesis can be diagnosed without objective testing and declined to exclude the defense expert. It held that any plaintiff claiming gastroparesis must show a diagnosis based on a properly performed gastric emptying study. That means scintigraphy, a breath test, or a wireless motility capsule.

Plaintiffs’ leadership has represented that the large majority of the docket pleads gastroparesis, so a single evidentiary ruling reset the qualification standard for most of the inventory. Verified claims and unverified claims stopped being worth the same thing on that date.

The second and third cross-cutting issues, warning adequacy with preemption and general causation, went to a five-day Rule 702 hearing that ran September 14 through 18, 2026. Closing arguments followed on October 13. No ruling has issued and it has no date. Judge Marston has status conferences set for November 17 and December 15, and no bellwether trial schedule exists.

The asymmetry is worth naming: a ruling for the plaintiffs moves more than 4,000 cases toward bellwethers. A ruling the other way leaves a docket that grew every month for two years with no admissible path to a jury. The docket’s count rose by only 3 in the October report, after months at roughly 80 to 95. The November report added 57. That is what a docket waiting on a causation ruling looks like.

The newest dockets on the board

The Panel centralized thirteen MDLs between June and early October 2026. Seven are commercial: two data breach dockets, two antitrust dockets, one patent docket, one securities docket, and the Amazon tariff refund docket. Six carry personal injury claims, and those are the ones a plaintiff-side firm reads first. They are Dupixent, three spinal cord stimulator dockets split by manufacturer, firefighter turnout gear made without AFFF, and Apple AirTag stalking.

Newest MDLs · centralized June–October 2026
DocketCentralizedCourtPending Nov 2
Apple AirTag stalking (MDL 3199)Oct 2N.D. Cal. · Wise29
Amazon tariff refunds (MDL 3197)Oct 2W.D. Wash. · Chun7
Nevro spinal cord stimulator (MDL 3195)Oct 2N.D. Cal. · Gilliam24
Abbott spinal cord stimulator (MDL 3194)Oct 2N.D. Ill. · Jenkins27
Non-AFFF firefighter turnout gear (MDL 3191)Aug 18D. Minn. · Bryan17
CoStar antitrust (MDL 3192)Aug 11E.D. Va. · Novak3
Health Gorilla data breach (MDL 3193)Aug 7S.D. Fla. · Moore10
Valtrus patent (MDL 3190)Aug 7E.D. Tex. · Gilstrap21
Norada securities (MDL 3189)Aug 7C.D. Cal. · Williams Court46
NPK fertilizer antitrust (MDL 3187)Jun 9D. Kan. · Melgren45
Cognizant / TriZetto data breach (MDL 3185)Jun 5E.D. Mo. · Ross28
Boston Scientific spinal cord stimulator (MDL 3181)Jun 5C.D. Cal. · Staton62
Dupixent (MDL 3180)Jun 4D.N.J. · Quraishi40

The new product dockets are growing. Boston Scientific went from 41 pending actions on October 1 to 62 on November 2, and the turnout gear docket went from 10 to 17. The four dockets the Panel created on October 2 each opened with more actions than their transfer orders named. On the November 2 report AirTag held 29 against 17, Abbott 27 against 15, and Nevro 24 against 17. None is large enough to price yet.

The November 2 report is the first to carry the four dockets the Panel created on October 2, from its September 24 hearing in Chicago. A fifth petition on that hearing calendar, over the 2026 multistate cyclosporiasis outbreak, was withdrawn before argument. The Panel’s next hearing session is December 3 in New Orleans.

Ecosystem defendants are now the norm

The defendants in these dockets are rarely a single manufacturer anymore. PFAS names the chemical, formulation, manufacturing, distribution, and successor chain, reaching the principal chemical companies and their corporate descendants. GLP-1 names both Novo Nordisk and Eli Lilly across a drug class spanning eight branded products, while the court separates the claims by injury rather than by manufacturer. Talc has pulled consumer-product allegations into a litigation built on industrial asbestos. The practical drafting implication: defendant identity is a corporate-family question, not a product question.

6. What it means for plaintiff-side practice

Two operational shifts follow from the data. First, Rule 16.1, effective December 1, 2025, formalizes early case management: leadership structure, discovery planning, and early identification of the factual and legal issues. Expect courts and defendants to press sooner for proof of product use, exposure, diagnosis, and injury timing. The documentation burden moves forward in the case, which means intake quality, not intake volume, is where the risk now sits.

Second, the verdict turn changes how a docket should be read. A bellwether outcome is a data point about a single plaintiff, not a verdict on the inventory. The PowerPort result, prevailing on warnings while hanging on design defect, is the textbook example. Treating one bellwether as dispositive, in either direction, is the most common analytical error of the cycle.

The strategic picture for the plaintiff bar is a barbell. At one end sit the proven mega-dockets (talc, AFFF, hair relaxer), with known injury definitions and recognizable defendants. The first of those evidentiary motions has now been decided in part. On October 22 Judge Rowland admitted the hair relaxer plaintiffs’ epidemiologist and most of their toxicologist, with eight more experts still to be ruled on. The same day she named the first five bellwether cases, none of which has a trial date.

At the other end sit the dockets still taking in the most new cases: social media, Bard PowerPort and Uber passenger assault. The law in each is being made in real time. Platform-safety claims are the coherent new category there, and the October 2 AirTag order extends it from apps to a consumer device.

Depo-Provera has left that end for the settlement window. The thin middle is the speculative theory the JPML has shown it will refuse to centralize.

Sources & method

Case counts are drawn from the JPML's pending-dockets and monthly statistics reports, anchored to the November 2, 2026 report; counts are point-in-time and move monthly. Month-over-month changes compare the November 2, 2026 and October 1, 2026 editions of the pending-dockets-by-actions-pending report. Centralization dates come from the date-transferred column of the pending-dockets-by-MDL-number report of November 2, 2026. That column records the date of the Panel's transfer order. The same report carries a separate date-filed column, which records when the petition reached the Panel.

The four MDLs created on October 2, 2026, and the October 2 denials, are taken from the Panel’s own orders. Those are the transfer orders and orders denying transfer for MDLs 2789, 3194, 3195, 3197, 3198 and 3199, published on its Panel Orders page.

Verdicts, settlements, and procedural milestones are compiled from court records and litigation reporting by Reuters, Law.com/ALM, NPR, CNBC, and established docket trackers. Settlement terms described as proposed or signed but not finalized are reported as such; confidential terms are not reconstructed here. The GLP-1 orders and hearing dates are taken from the docket in MDL 3094, No. 2:24-md-03094-KSM (E.D. Pa.).

The interactive map, board, trend lines and docket focus read from a data block embedded in this page. That block is compiled from the by-actions-pending, by-district and by-type editions of the JPML reports, February 2025 through November 2, 2026. Each layer names its edition in its caption. Figures should be re-verified against primary sources before republication. Nothing here is legal advice.

Citing these figures. The case counts come from public JPML reports. Use them in a client memo, a pitch deck, a newsletter or a post. Cite Lawsuit Intelligencer with a link to this page, so your reader can check which month the numbers come from. Reproducing a table as it is arranged here, one of the charts, or a passage of the analysis asks for the same credit and link. To run the piece in full, write to editor@lawsuitintelligencer.com.

Update log

  • Moved the district map and docket board to the top of the page. The pending-action, MDL and concentration counts sit above them, and the analysis follows.
  • Added the ruling behind the Paragard drop. On October 28, Judge May granted Teva’s second motion to dismiss Paragard cases barred by statutes of limitations and repose. Paragard fell by 120 pending actions between the October and November reports.
  • Moved to the Panel’s November 2, 2026 report. 204,987 pending actions across 164 MDLs, up 10 from October 1, 2026. Social media adolescent addiction added the most, 485. Four new dockets carry a first count. Two left the report.
  • Added a docket focus view. It follows one MDL across one to twelve monthly reports and fits a trendline to them.
  • Added three interactive layers. A district map, a docket board and trend lines, each built from the Panel’s monthly reports.
  • Added the Panel’s October 2 orders. From its September 24 hearing, the Panel created four MDLs and refused two. The new dockets include separate spinal cord stimulator MDLs for Abbott and Nevro and an Apple AirTag stalking docket.
  • Added two tables. One ranks the dockets that grew between the September 1 and October 1 reports. The other lists the MDLs the Panel centralized most recently.
  • Moved to the Panel’s October 1 report. Both headline counts fell. The same update added the Ninth Circuit’s holding that Section 230 operates as a defense to liability. It also added Meta’s 47-state settlement and the settlement terms J&J and Pfizer each put on paper.

Disclosure: The editor owns and operates Lawsuit Informer and Lawsuit Center, consumer-facing sites that publish educational material on several of the litigations discussed here. This piece is industry analysis, not case solicitation, and references no specific intake program.

More from Lawsuit Intelligencer

  1. The Handwritten Line in the ChatGPT Leadership Order

    CMO No. 1 in the coordinated ChatGPT product liability cases appoints the usual leadership and bars everyone else from filing on liability. Then the judge added a line by hand preserving a self-represented plaintiff's right to be heard. The mechanics are worth reading closely.

    By David Meldofsky · 8 min read

  2. MDL 3026 Finally Has a Jury in the NEC Docket

    Three federal bellwethers never reached a jury. The fourth is being tried in Chicago now, and what it actually tests is not the epidemiology but whether a better warning would have changed how one NICU fed one infant.

    By David Meldofsky · 7 min read